secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001193125-25-033539
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen enters ATM equity offering agreement for up to $30M with BofA Securities
--------------------------------------------------------------------------------

- May sell up to $30M of common stock from time to time through BofA as sales agent.
- BofA will receive a commission of up to 3.0% of gross sales proceeds.
- Company is not obligated to sell any shares; offering may terminate upon sale of all shares or by agreement.
- Shares sold under effective shelf registration (333-280597) and prospectus supplement dated Feb 24, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312525033539/0001193125-25-033539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312525033539/d921088d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-033539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer